Burren Capital Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$696K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RP
RealPage, Inc.
RP
|
+$1.35M |
| 2 |
BEAT
BioTelemetry, Inc.
BEAT
|
+$706K |
| 3 |
CATM
Cardtronics plc Class A Ordinary Shares (UK)
CATM
|
+$648K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 64.73% |
| 2 | Financials | 27.08% |
| 3 | Healthcare | 8.2% |
| 4 | Industrials | 0% |
Similar funds
Burren Capital Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Burren Capital Advisors held 6 positions worth $8.39M, down 19% from $10.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Burren Capital Advisors withdrew a net $2.01M in Q1 2021, closing 2 positions and reducing 1 holding. Its most notable exit was BioTelemetry, Inc., an estimated $706K position sold in full.
By sector, the portfolio is most concentrated in Technology at 65% of assets, down from 67% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Burren Capital Advisors opened a new position in Alexion Pharmaceuticals worth $688K.
- Burren Capital Advisors's largest Q1 2021 buy was Alexion Pharmaceuticals: 4,500 shares worth $688K.
- Burren Capital Advisors's biggest Q1 2021 reduction was RealPage, Inc., cutting an estimated $1.35M.
- Burren Capital Advisors fully exited BioTelemetry, Inc. in Q1 2021, selling an estimated $706K.
- Burren Capital Advisors's ten largest holdings make up 100% of its $8.39M portfolio in Q1 2021.
- Burren Capital Advisors opened 1 new position and closed 2 in Q1 2021.
- Burren Capital Advisors's portfolio value fell 19% quarter-over-quarter to $8.39M.
Based on Burren Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.